Answers are grounded in this paper and cite their sources.
Observational study highlights prognostic impact of FLT3 mutation in acute promyelocytic leukaemia, suggesting interventions may enhance outcomes.
Background: Acute promyelocytic leukaemia (APML), classified as the M3 subtype by the FAB group and the World Health Organization in 2022, is known for its favourable prognosis when treated promptly despite life-threatening coagulopathy. Despite generally favourable outcomes with targeted therapy, genetic heterogeneity such as FLT3 mutation may influence prognosis. This study aimed to evaluate the clinicopathological features and prognostic impact of FLT3 mutation in APML patients on the East Coast of Malaysia.
No takes yet. Share an insight, caveat, or question.
Zulkeflee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: